Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
Trial Details
- NCT ID
- NCT03382977
- Phase
- PHASE1 / PHASE2
- Sponsor
- VBI Vaccines Inc.
- Status
- RECRUITING
- Cancer Type
- Brain Cancer
- Interventions
- VBI-1901
- Carmustine
- Lomustine
- Locations (sample)
- Irvine, California, United States|33.66946,-117.82311
- La Jolla, California, United States|32.84727,-117.2742
- Los Angeles, California, United States|34.05223,-118.24368
- Stanford, California, United States|37.42411,-122.16608
- Miami, Florida, United States|25.77427,-80.19366
Key Eligibility Criteria
- 18-70 years of age
- Histologically confirmed WHO grade IV glioblastoma
- Unequivocal evidence of a tumor recurrence (any number of recurrences) or progression after an initial treatment regimen (prior to enrollment on th…
- Recovery from the effects of surgery.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Brain Cancer Trials on Trialify →